Metabolic & Endocrine · Clinical trials
Osteoporosis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About osteoporosis — and why its trials are hard
Osteoporosis is a systemic skeletal disease of reduced bone mass and microarchitectural deterioration that increases bone fragility and fracture risk, particularly at the spine, hip, and wrist. It is most common in postmenopausal women and older adults, and fractures carry substantial morbidity, mortality, and cost. Therapy divides into antiresorptive agents, which slow bone breakdown, and anabolic agents, which build new bone. Oral and intravenous bisphosphonates (alendronate, risedronate, zoledronic acid) are first-line antiresorptives with proven fracture reduction. Denosumab (Prolia), a RANK-ligand inhibitor, reduced vertebral, nonvertebral, and hip fractures in the FREEDOM trial. Anabolic options include teriparatide and abaloparatide (PTH-pathway agents) and romosozumab (Evenity), a sclerostin antibody with dual bone-forming and antiresorptive effects that reduced fractures in FRAME (versus placebo) and ARCH (versus alendronate). Sequential strategies, typically an anabolic agent followed by an antiresorptive to consolidate gains, are increasingly favored for high-risk patients. Emphasis on adherence, calcium/vitamin D sufficiency, fall prevention, and fracture-risk stratification underpins effective, individualized long-term management.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Romosozumab (Evenity) | 2019 | Anabolic (anti-sclerostin) therapy for postmenopausal women at high fracture risk | FRAME (vs placebo) and ARCH (vs alendronate), Phase 3 (NEJM 2016/2017) | New vertebral fracture incidence; nonvertebral/clinical fractures | FRAME: ~73% reduction in new vertebral fractures at 12 months vs placebo; ARCH: ~48% reduction in new vertebral fractures vs alendronate at 24 months |
| Denosumab (Prolia) | 2010 | RANK-ligand inhibitor antiresorptive for postmenopausal osteoporosis at high risk | FREEDOM Phase 3 (NEJM 2009) | New vertebral fractures at 36 months; nonvertebral and hip fractures | 68% reduction in new vertebral, 20% in nonvertebral, and 40% in hip fractures versus placebo |
| Zoledronic acid (Reclast) | 2007 | Once-yearly intravenous bisphosphonate for postmenopausal osteoporosis | HORIZON Pivotal Fracture Trial (NEJM 2007) | Morphometric vertebral fracture and hip fracture over 3 years | 70% reduction in vertebral fractures and 41% reduction in hip fractures versus placebo |
| Teriparatide (Forteo) | 2002 | PTH(1-34) anabolic therapy for severe/high-risk osteoporosis | Fracture Prevention Trial (Neer et al., NEJM 2001) | New vertebral and nonvertebral fractures | ~65% reduction in new vertebral and ~53% in nonvertebral fractures versus placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in osteoporosis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Odanacatib (cathepsin K inhibitor) — LOFT Phase 3 | Reduced fractures but development halted in 2016 after an increased risk of stroke (cerebrovascular events) emerged | Efficacy on bone was outweighed by an adjudicated cardiovascular/stroke safety signal; Merck discontinued the program |
| Romosozumab (cardiovascular safety) — ARCH | Numerical imbalance in serious cardiovascular events versus alendronate led to a boxed warning rather than program failure | MI/stroke/CV-death signal in ARCH (not seen versus placebo in FRAME) restricted use in patients with recent cardiovascular events |
| Calcitonin (salmon, nasal) — PROOF and later reviews | Weak and inconsistent fracture efficacy; use curtailed after long-term cancer-risk signal | Marginal antifracture benefit plus a possible malignancy association led regulators to restrict chronic use |
Choosing the right endpoint
Primary endpoints that matter in osteoporosis trials
- New vertebral fracture incidence — Most common primary endpoint; morphometric fractures detected on spine radiographs
- Nonvertebral and hip fracture — Clinically important secondary endpoints; hip fracture drives mortality and cost
- Bone mineral density (DXA, spine/hip) — Surrogate marker of treatment response and adherence; not a substitute for fracture data
- Bone turnover markers (P1NP, CTX) — Reflect anabolic (formation) versus antiresorptive activity and monitor therapy
How iNGENū runs osteoporosis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Osteoporosis clinical trials — FAQs
What is the difference between antiresorptive and anabolic drugs?
How effective is romosozumab?
Why is treatment sequencing important?
Ready to discuss your osteoporosis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal